Sullivan 1991.

Methods	Randomised, parallel group, multicentre trial (North America). ITT: unclear. Withdrawals: stated.
Participants	Baseline characteristics: 168 participants registered, 148 were evaluable, 73 had BL. Median age: 8.7 years (range 0.7 to 18.7), male:female; 4.4:1.0. Tumour staging: Murphy. Diagnosis: unclear (institutional review). Entry criteria: stages III and IV non lymphoblastic NHL, age < 22 years. Exclusion criteria: not stated.
Interventions	Triple IT (Ara‐C, MTX, HYD) given for short (2 months) versus long (6 months) term as maintenance treatment. Follow‐up: 3 to 7 years.
Outcomes	Complete remission. Event‐free survival. Toxicity.
Notes	Full text publication. Study type: remission induction.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not described.
Allocation concealment (selection bias)	Unclear risk	Not described.
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Not described.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Outcomes described